126 related articles for article (PubMed ID: 9384505)
41. Chronic dosing with aminoguanidine and novel advanced glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats.
Kochakian M; Manjula BN; Egan JJ
Diabetes; 1996 Dec; 45(12):1694-700. PubMed ID: 8922353
[TBL] [Abstract][Full Text] [Related]
42. Effect of aminoguanidine on the frequency of neuroaxonal dystrophy in the superior mesenteric sympathetic autonomic ganglia of rats with streptozocin-induced diabetes.
Schmidt RE; Dorsey DA; Beaudet LN; Reiser KM; Williamson JR; Tilton RG
Diabetes; 1996 Mar; 45(3):284-90. PubMed ID: 8593931
[TBL] [Abstract][Full Text] [Related]
43. In vitro advanced glycation end product formation in rat tail tendon fibers: influence of aminoguanidine.
Troncoso IA; Esteban MM; Ruiz MA; Flórez L; Barneo L
Transplant Proc; 1995 Dec; 27(6):3345-6. PubMed ID: 8539985
[No Abstract] [Full Text] [Related]
44. [Aminoguanidine prevents peroxynitrite production and cardiac hypertrophy in streptozotocin-induced diabetic rats].
Stadler K; Jenei V; Somogyi A; Jakus J
Orv Hetil; 2004 Dec; 145(49):2491-6. PubMed ID: 15633737
[TBL] [Abstract][Full Text] [Related]
45. Influence of verapamil and diclofenac on leukocyte migration in rats.
Martinez LL; Aparecida De Oliveira M; Fortes ZB
Hypertension; 1999 Oct; 34(4 Pt 2):997-1001. PubMed ID: 10523397
[TBL] [Abstract][Full Text] [Related]
46. Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus.
Ellis EN; Good BH
Metabolism; 1991 Oct; 40(10):1016-9. PubMed ID: 1943726
[TBL] [Abstract][Full Text] [Related]
47. [Effect of aminoguanidine on oxidative modification of proteins in experimental diabetes mellitus in rats].
Brodiak IV; Sybirna NO
Ukr Biokhim Zh (1999); 2006; 78(5):114-9. PubMed ID: 17290789
[TBL] [Abstract][Full Text] [Related]
48. [Inhibition of lipid peroxidation in erythrocytes by aminoguanidine, resorcylidine aminoguanidine and their oxygen and sulfur analogs in diabetic rats].
Hrnciarová M; Cársky J; Jakuś V; Zlatos L; Kucharská J; Gvozdjáková A
Bratisl Lek Listy; 1998 Jul; 99(7):364-7. PubMed ID: 9748726
[TBL] [Abstract][Full Text] [Related]
49. Aminoguanidine reduces regional albumin clearance but not urinary albumin excretion in streptozotocin-diabetic rats.
Huijberts MS; Wolffenbuttel BH; Crijns FR; Nieuwenhuijzen Kruseman AC; Bemelmans MH; Struijker Boudier HA
Diabetologia; 1994 Jan; 37(1):10-4. PubMed ID: 8150221
[TBL] [Abstract][Full Text] [Related]
50. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy.
Hammes HP; Martin S; Federlin K; Geisen K; Brownlee M
Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11555-8. PubMed ID: 1763069
[TBL] [Abstract][Full Text] [Related]
51. Effect of aminoguanidine on optic nerve involvement in experimental diabetic rats.
Ino-ue M; Ohgiya N; Yamamoto M
Brain Res; 1998 Aug; 800(2):319-22. PubMed ID: 9685690
[TBL] [Abstract][Full Text] [Related]
52. Secreted glucocorticoids regulate leukocyte-endothelial interactions in inflammation. A direct vital microscopic study.
Farsky SP; Sannomiya P; Garcia-Leme J
J Leukoc Biol; 1995 Mar; 57(3):379-86. PubMed ID: 7884308
[TBL] [Abstract][Full Text] [Related]
53. Aminoguanidine treatment reduces the increase in collagen stability of rats with experimental diabetes mellitus.
Oxlund H; Andreassen TT
Diabetologia; 1992 Jan; 35(1):19-25. PubMed ID: 1541376
[TBL] [Abstract][Full Text] [Related]
54. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.
Brownlee M; Vlassara H; Kooney A; Ulrich P; Cerami A
Science; 1986 Jun; 232(4758):1629-32. PubMed ID: 3487117
[TBL] [Abstract][Full Text] [Related]
55. The effect of aminoguanidine on urinary heparan sulphate levels in experimental diabetes.
Unlüçerçi YM; Bekpinar S; Seferoglu G
Acta Diabetol; 2000; 37(2):71-6. PubMed ID: 11194930
[TBL] [Abstract][Full Text] [Related]
56. Collagen and bladder function in streptozotocin-diabetic rats: effects of insulin and aminoguanidine.
Eika B; Levin RM; Longhurst PA
J Urol; 1992 Jul; 148(1):167-72. PubMed ID: 1535382
[TBL] [Abstract][Full Text] [Related]
57. Transmission electron microscopy and autofluorescence findings in the cornea of diabetic rats treated with aminoguanidine.
Yücel I; Yücel G; Akar Y; Demir N; Gürbüz N; Aslan M
Can J Ophthalmol; 2006 Feb; 41(1):60-6. PubMed ID: 16462874
[TBL] [Abstract][Full Text] [Related]
58. Comparison of the effects of aminoguanidine and L-carnitine treatments on somatosensorial evoked potentials in alloxan-diabetic rats.
Yildiz O; Ozata M; Ozkardeş A; Deniz G; Yildirimkaya M; Corakçi A; Yardim M; Gündoğan MA
Naunyn Schmiedebergs Arch Pharmacol; 1996 Oct; 354(4):526-31. PubMed ID: 8897458
[TBL] [Abstract][Full Text] [Related]
59. Aminoguanidine, a potential drug for the treatment of diabetic complications.
Wolffenbuttel BH; Huijberts MS
Neth J Med; 1993 Jun; 42(5-6):205-8. PubMed ID: 8377878
[No Abstract] [Full Text] [Related]
60. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications.
Vlassara H; Fuh H; Makita Z; Krungkrai S; Cerami A; Bucala R
Proc Natl Acad Sci U S A; 1992 Dec; 89(24):12043-7. PubMed ID: 1465438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
